Clinician's Comment on the Management of Pain in Arthritis

Health Psychology

Volumn 26, Issue 6, 2007, Pages 657-659

  Pisetsky, David S ^a  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIDEPRESSANT AGENT; ANTIINFLAMMATORY AGENT; CORTICOSTEROID; DISEASE MODIFYING ANTIRHEUMATIC DRUG; IMMUNOSUPPRESSIVE AGENT; METHOTREXATE; NARCOTIC ANALGESIC AGENT; NONSTEROID ANTIINFLAMMATORY AGENT; STEROID; TUMOR NECROSIS FACTOR ALPHA INHIBITOR;

ARTHRALGIA; ARTHRITIS; ARTICLE; BONE DESTRUCTION; CARTILAGE DEGENERATION; CLINICAL DECISION MAKING; DRUG EFFICACY; DRUG MECHANISM; HUMAN; NEUROPATHIC PAIN; OSTEOARTHRITIS; PAIN; PAIN ASSESSMENT; PATHOGENESIS; PATHOPHYSIOLOGY; PSYCHOSOCIAL CARE; RHEUMATOID ARTHRITIS; SYNOVIUM;

ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; COMBINED MODALITY THERAPY; HUMANS; OSTEOARTHRITIS; PSYCHOTHERAPY;

EID: 36349014798     PISSN: 02786133     EISSN: None     Source Type: Journal    
DOI: 10.1037/0278-6133.26.6.657     Document Type: Article

References (16)

1. Aigner T., Sachse A., Gebhard P.M., and Roach H.I. Osteoarthritis: Pathobiology-Targets and ways for therapeutic intervention. Advanced Drug Delivery Reviews 58 (2006) 128-149
2. Aletaha D., and Smolen J. The Simplified Disease Activity Index (SDAI) and the Clinical Disease Activity Index (CDAI): A review of their usefulness and validity in rheumatoid arthritis. Clinical and Experimental Rheumatology 23 (2005) S100-S108
3. Aletaha D., and Smolen J. The definition and measurement of disease modification in inflammatory rheumatic diseases. Rheumatic Diseases Clinics of North America 32 (2006) 9-44
4. Aletaha D., Smolen J., and Ward M.M. Measuring function in rheumatoid arthritis. Identifying reversible and irreversible components. Arthritis and Rheumatism 54 (2006) 2784-2792
5. Aletaha D., Ward M.M., Machold K.P., and Nell V.P.K. Remission and active disease in rheumatoid arthritis. Defining criteria for disease activity states. Arthritis and Rheumatism 52 (2005) 2625-2636
6. Cohen S.B., Emery P., Greenwald D.W., Dougados M., Furie R.A., Genovese M.C., et al. Rituximab for rheumatoid arthritis refractory to anti-tumor necrosis factor therapy: Results of a multicenter, randomized, double-blind, placebo-controlled, phase III trial evaluating primary efficacy and safety at twenty-four weeks. Arthritis and Rheumatism 54 (2006) 2793-2806
7. Dixon K.E., Keefe F.J., Scipio C.D., Perri L.M., and Abernethy A.P. Psychological interventions for arthritis pain management in adults: A meta-analysis. Health Psychology 26 (2007) 241-250
8. Firestein G.S. Evolving concepts of rheumatoid arthritis. Nature 423 (2003, May 15) 356-361
9. Ge Z., Hu Y., Heng B.C., Yang Z., Ouyang H., Lee E.H., and Cao T. Osteoarthritis and therapy. Arthritis and Rheumatism 55 (2006) 493-500
10. Kidd B.L. Topical review: Osteoarthritis and joint pain. Pain 123 (2006) 1-6
11. Kremer J.M., Genant H.K., Moreland L.W., Russell A.S., Emery P., Abud-Mendoza C., et al. Effects of abatacept in patients with methotrexate-resistant active rheumatoid arthritis. Annals of Internal Medicine 144 (2006) 856-876
12. Landewé R., van der Heijde D., Klareskog L., van Vollenhoven R., and Fatenejad S. Disconnect between inflammation and joint destruction after treatment with etanercept plus methotrexate. Results from the trial of etanercept and methotrexate with radiographic and patient outcomes. Arthritis and Rheumatism 54 (2006) 3119-3125
13. O'Dell J.R. Therapeutic strategies for rheumatoid arthritis. New England Journal of Medicine 350 (2004) 2591-2602
14. Olsen N.J., and Stein C.M. Drug therapy: New drugs for rheumatoid arthritis. New England Journal of Medicine 350 (2004) 2167-2179
15. Pisetsky D.S., and St. Clair E.W. Progress in the treatment of rheumatoid arthritis. Journal of the American Medical Association 286 (2001) 2787-2790
16. Smolen J.S., Aletaha D., and Machold K.P. Therapeutic strategies in early rheumatoid arthritis. Best Practice & Research: Clinical Rheumatology 19 (2005) 163-177